Daniel J. Wallace

Daniel J. Wallace's AcademicInfluence.com Rankings

Daniel J. Wallace

Philosophy

#5790

World Rank

#8690

Historical Rank

#1464

USA Rank

Logic

#3005

World Rank

#4097

Historical Rank

#658

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Daniel J. Wallace Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Daniel Jeffrey Wallace is an American rheumatologist, clinical professor, author, and fellow. Wallace has published 500 peer reviewed publications, 9 textbooks, and 28 book chapters on topics such as lupus, Sjögren syndrome, osteoarthritis, and fibromyalgia. He has the largest cohort of lupus patients in the United States . A full professor of medicine , he is associate director of the Rheumatology Fellowship Program at Cedars-Sinai. His seminal contributions to research include being an author of the first paper to demonstrate vitamin D dysfunction and the importance of interleukin 6 in lupus, conducting the first large studies of apheresis in rheumatoid arthritis and lupus, and insights into the mechanisms of action of antimalarials. Wallace's research accomplishments also include conducting many clinical rheumatic disease trials, examining the role of microvascular angina and accelerated atherogenesis in lupus, and work on anti-telomere antibodies which have garnered him 6 papers in The New England Journal of Medicine. Wallace's monograph, The Lupus Book, has sold over 100,000 copies since 1995.

(See a Problem?)

Daniel J. Wallace's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2011) (3649)
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. (1999) (1841)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. (2011) (1208)
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis (2012) (1149)
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. (2010) (1089)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (2019) (936)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. (2005) (673)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). (2005) (642)
Dubois' Lupus Erythematosus (1987) (637)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. (2003) (584)
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. (2009) (540)
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (2019) (419)
Telomere diseases. (2010) (412)
Novel evidence-based systemic lupus erythematosus responder index. (2009) (412)
Lupus erythematosus in the 1980s: a survey of 570 patients. (1991) (406)
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. (2006) (390)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2014) (377)
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. (2010) (345)
Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. (1999) (326)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (2018) (325)
Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. (2001) (324)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. (2007) (308)
The frequency and outcome of lupus nephritis: results from an international inception cohort study. (2016) (301)
Systemic lupus erythematosus--survival patterns. Experience with 609 patients. (1981) (295)
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. (1997) (287)
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. (2007) (285)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study (2013) (280)
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. (1999) (279)
Transancestral mapping and genetic load in systemic lupus erythematosus (2017) (253)
Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study (2013) (250)
The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. (2006) (242)
Cancer risk in systemic lupus: an updated international multi-centre cohort study. (2013) (242)
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study (2011) (241)
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus (2009) (236)
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. (1990) (229)
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. (2012) (189)
New insights into mechanisms of therapeutic effects of antimalarial agents in SLE (2012) (185)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study (2015) (183)
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. (2006) (172)
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). (2008) (171)
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. (2009) (162)
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus (2014) (155)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials (2016) (149)
Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. (2011) (143)
Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. (2008) (143)
Antimalarial agents and lupus. (1994) (142)
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids (2011) (141)
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus (2011) (138)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort (2012) (135)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus (2017) (133)
A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing (2004) (133)
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study (2012) (132)
The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. (1989) (131)
Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. (1982) (127)
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? (1987) (124)
PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. (1999) (117)
Disease-specific patient reported outcome tools for systemic lupus erythematosus. (2012) (115)
Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis (1998) (113)
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. (2013) (113)
Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. (1979) (112)
Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. (1995) (112)
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2012) (111)
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study (2007) (111)
A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus (2014) (110)
Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. (1988) (110)
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. (2012) (109)
Lymphoma risk in systemic lupus: effects of disease activity versus treatment (2012) (105)
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis (2013) (105)
Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus Erythematosus (2010) (105)
Gastrointestinal manifestations of systemic lupus erythematosus (2000) (102)
Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. (2010) (100)
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA (2010) (97)
Benefyts of lefiunomide in systemic lupus erythematosus: a pilot observational study (2001) (97)
X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome (2015) (96)
A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. (1982) (94)
The fibromyalgia syndrome. (1997) (93)
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. (2013) (93)
The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE (1993) (91)
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. (2005) (90)
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. (2008) (90)
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial (2016) (90)
Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial (2012) (89)
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2014) (87)
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. (2013) (84)
Is there a role for cytokine based therapies in fibromyalgia. (2006) (84)
Low physical activity is associated with proinflammatory high‐density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus (2010) (78)
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices (2015) (77)
Cyclosporine for lupus membranous nephritis:experience with ten patients and review of the literature (2000) (76)
The lupus family registry and repository. (2011) (75)
Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus (2007) (75)
Brain Magnetic Resonance Imaging in Newly Diagnosed Systemic Lupus Erythematosus (2008) (74)
False-positive human immunodeficiency virus testing in patients with lupus erythematosus. (1993) (72)
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. (2008) (70)
Impact of systemic lupus erythematosus on health, family, and work: The patient perspective (2010) (70)
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2014) (69)
Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. (2005) (69)
Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? (2007) (68)
Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort (2019) (67)
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus (2019) (66)
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006 (2013) (66)
Should a war criminal be rewarded with eponymous distinction?: the double life of hans reiter (1881-1969). (2000) (66)
Dubois' Lupus Erythematosus and Related Syndromes (2018) (65)
Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. (2007) (64)
25‐Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort (2014) (63)
Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features. (1992) (63)
Cognitive function in a systemic lupus erythematosus inception cohort. (2008) (63)
Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. (2016) (63)
Predictors of preterm birth in patients with mild systemic lupus erythematosus (2013) (61)
Fibromyalgia: The gastrointestinal link (2004) (59)
Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. (1994) (58)
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus. (2002) (58)
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (55)
Familiality and co-occurrence of clinical features of systemic lupus erythematosus. (2002) (54)
The role of stress and trauma in rheumatoid arthritis and systemic lupus erythematosus. (1987) (54)
Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons (2017) (52)
Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus (2018) (51)
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus (2011) (51)
Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. (2011) (50)
MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. (2017) (50)
Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus (2008) (49)
Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: Design of the LPSG trial (1991) (48)
Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. (2005) (48)
Fibromyalgia and interleukin-2 therapy for malignancy. (1988) (48)
Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials (2015) (47)
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals (2019) (47)
The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study (2009) (47)
Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort (2015) (47)
Sex chromosome aneuploidies among men with systemic lupus erythematosus. (2012) (46)
Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. (2007) (46)
Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus (2014) (46)
Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials (2016) (46)
Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features (2017) (46)
The evolution of drug discovery in systemic lupus erythematosus (2015) (45)
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2018) (45)
Advances in drug therapy for systemic lupus erythematosus (2010) (45)
The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. (1994) (44)
Decreased live births in women with systemic lupus erythematosus (2011) (44)
Apheresis for lupus erythematosus (1999) (44)
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study (2015) (44)
Coexistent gout and rheumatoid arthritis (1979) (43)
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. (2008) (43)
New therapies in systemic lupus erythematosus. (2002) (43)
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients (2017) (43)
Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. (1985) (42)
New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus (2012) (42)
Development and Validation of the Lupus Impact Tracker: A Patient‐Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus (2014) (42)
Apheresis for lupus erythematosus: state of the art (2001) (39)
Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study (2016) (39)
Cytokines and immune regulation in patients with fibrositis. (1989) (39)
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2019) (38)
Management of lupus erythematosus: recent insights (2002) (38)
Advances in the use of therapeutic pheresis for the management of rheumatic diseases. (1980) (37)
Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus (2016) (37)
Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis (2014) (37)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort (2018) (36)
Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. (2016) (36)
BELIMUMAB, A BLYS-SPECIFIC INHIBITOR, REDUCES DISEASE ACTIVITY AND SEVERE FLARES IN SEROPOSITIVE SLE PATIENTS (2011) (35)
Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans (2018) (35)
Disease-specific quality of life in patients with lupus nephritis (2018) (35)
Unique Sjögren's syndrome patient subsets defined by molecular features. (2020) (35)
Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus (2004) (35)
LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus (2004) (34)
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. (1997) (34)
Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China (2012) (34)
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2020) (33)
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach (2016) (32)
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020) (32)
Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus (2013) (30)
Genitourinary manifestations of fibrositis: an increased association with the female urethral syndrome. (1990) (30)
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus (2019) (30)
Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE (2002) (30)
Pierre Cazenave and the first detailed modern description of lupus erythematosus. (1999) (30)
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin &bgr; Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) (29)
Predictive value of clinical, laboratory, pathologic, and treatment variables in steroid/lmmunosuppressive resistant lupus nephritis (1988) (29)
Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs) (2008) (29)
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways (2020) (28)
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort (2014) (28)
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus (2019) (28)
Spanish LupusPRO: cross-cultural validation study for lupus (2013) (28)
The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947). (2003) (28)
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach (2020) (27)
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome (2018) (27)
Breast Cancer in Systemic Lupus Erythematosus (2013) (27)
Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a Large, Ethnically Diverse SLE Patient Cohort (2012) (27)
Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. (2016) (27)
Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome (2017) (27)
The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious. (2003) (26)
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus (2019) (26)
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial (2018) (26)
How accelerated atherosclerosis in SLE has changed our management of the disorder (2000) (26)
Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus (2019) (26)
Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. (2007) (26)
Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-Induced Lupus Model (2020) (26)
Effect of Tobacco Smoking on The Clinical, Histopathological, and Serological Manifestations of Sjögren’s Syndrome (2017) (25)
Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus (2018) (25)
IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. (2018) (25)
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study (2020) (25)
NSAID usage patterns by rheumatologists in the treatment of SLE. (1989) (25)
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021) (25)
The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study (2008) (25)
OP0020 Validation of new systemic lupus erythematosus classification criteria (2018) (24)
Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience (2017) (24)
Lupus registries: evolution and challenges. (2010) (24)
Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients (2017) (24)
Systemic lupus erythematosus: considerations for a genetic approach. (1994) (23)
Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. (1998) (23)
Pain and depression predict self-reported fatigue/energy in lupus (2013) (23)
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. (2020) (22)
Mycophenolate mofetil for systemic lupus erythematosus. (1999) (22)
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. (2008) (22)
A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus (2018) (22)
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products (2016) (22)
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. (1996) (21)
Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia (2001) (21)
Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation. (2007) (21)
Osteoporosis--less than expected in patients with scleroderma? (2000) (21)
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (21)
Coexistent gout and rheumatoid arthritis. Case report and literature review. (1979) (21)
The ‘Rule Out Lupus’ Rheumatology Consultation: Clinical Outcomes and Perspectives (1995) (21)
Update on fibromyalgia syndrome. (1999) (20)
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2021) (20)
Plasmapheresis in Lupus (1993) (19)
Can an earthquake cause flares of rheumatoid arthritis or lupus nephritis? (1994) (19)
The management of fibromyalgia-associated syndromes. (2002) (19)
Risk factors for avascular necrosis in systemic lupus erythematosus. (1998) (19)
Efficacy and safety of epratuzumab in patients with moderate / severe active systemic lupus erythematosus : results from EMBLEM , a phase (2013) (18)
Anti-telomere antibodies in systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications (2000) (18)
A brief assessment tool for body image in systemic lupus erythematosus. (2012) (18)
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach (2018) (18)
Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. (2008) (18)
The psychometric properties of the Perceived Stress Scale-10 among patients with systemic lupus erythematosus (2017) (18)
Eligibility, utilization, and costs in a California Medicaid lupus population. (2004) (17)
Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox (2008) (17)
Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment (2018) (17)
Clinical and pharmacological experience with LJP-394 (2001) (17)
Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America (2019) (16)
Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus (2018) (16)
A promising approach to targeting type 1 IFN in systemic lupus erythematosus (2019) (16)
Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus (2017) (16)
Occasional Review: Use of hyperbaric oxygen in rheumatic diseases: case report and critical analysis (1995) (16)
Does stress or trauma cause or aggravate rheumatic disease? (1994) (16)
Therapeutic trial of cryofiltration in patients with rheumatoid arthritis. (1983) (16)
Five‐Year Follow‐Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community‐Based Lupus Cohort (2020) (15)
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. (2020) (15)
Joint scanning in rheumatoid arthritis: a literature review. (1981) (15)
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort (2018) (14)
A reason for the rarity of male lupus (1998) (14)
It's not the same old lupus or Sjögren's any more: one hundred new insights, approaches, and options since 1990. (1999) (14)
Lupus, acquired immunodeficiency syndrome, and antimalarial agents. (1991) (13)
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach (2020) (13)
Editorial [Autoinflammatory Disorders of Childhood: Continued Major Breakthroughs] (2008) (13)
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort (2019) (13)
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus (2018) (12)
Plasmapheresis versus lymphoplasmapheresis in rheumatoid arthritis: Immunologic comparisons and literature review (1984) (12)
the Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results from a Randomized, Double-blind, Placebo-controlled Phase Ii Trial : abstract Number: 3203 (2015) (12)
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies (2021) (12)
Breast implants and connective-tissue diseases. (1994) (12)
Measuring preference weights for American college of rheumatology response criteria for patients with rheumatoid arthritis. (2005) (12)
Sample stability and variability of B‐cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus (2009) (11)
A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus (2021) (11)
Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus (2018) (11)
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort (2020) (10)
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE (2019) (10)
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. (2021) (10)
Eradication of small intestinal bacterial overgrowth decreases symptoms in chronic fatigue syndrome: A double blind, randomized study (2000) (10)
The elusive search for geographic clusters of systemic lupus erythematosus. Critical review. (1995) (10)
A Comparison of 2019 EULAR/ACR SLE Classification Criteria with Two Sets of Earlier SLE Classification Criteria. (2020) (9)
Microvascular Angina: An Underappreciated Cause of SLE Chest Pain (2013) (9)
Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria (2021) (9)
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (2021) (9)
Dubois' Lupus Erythematosus and Related Syndromes, 8th Edition (2012) (9)
Sex and arthritis. (2000) (9)
A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus (2019) (9)
Severe giant cell valvulitis in a patient with Reiter's syndrome. (1982) (9)
Plasmapheresis in lupus nephritis with nephrotic syndrome: A long‐term followup (1982) (9)
Monoclonal Antibodies, Systemic Lupus Erythematosus, and Pregnancy: Insights from an Open-label Study (2015) (8)
A Comparison of Systemic Lupus Erythematosus and Scleroderma Patients with and without Silicone Breast Implants (1996) (8)
Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. (2020) (8)
Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned (2017) (8)
Reconsidering Antimalarials in Systemic Lupus Erythematosus: Developments of Translational Clinical Interest (2012) (8)
The genetic basis of systemic lupus erythematosus. (1998) (8)
A critique of the NIH lupus nephritis survey. (1992) (8)
The Biology of Aging: 1976, An Overview † (1977) (8)
The lupus book : a guide for patients and their families (1995) (8)
CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE) (2016) (8)
Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE. (2019) (8)
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2022) (7)
Thirty-four-year delayed-onset lupus nephritis: a case report. (1987) (7)
Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE (2019) (7)
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. (2019) (7)
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2022) (7)
Subendocardial Ischemia and Myocarditis in Systemic Lupus Erythematosus Detected by Cardiac Magnetic Resonance Imaging (2012) (7)
Lupus: The Essential Clinician's Guide (2008) (7)
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study (2022) (7)
Rapid prevention of vertebral fractures associated with osteoporosis. (2005) (7)
Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial (2022) (7)
Drivers of Satisfaction With Care for Patients With Lupus (2019) (7)
American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans (2020) (7)
Reproducibility of Ocular Surface Staining in the Assessment of Sjögren Syndrome–Related Keratoconjunctivitis Sicca: Implications on Disease Classification (2019) (7)
Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience (2016) (6)
Plasmapheresis for lupus nephritis. (1992) (6)
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. (2021) (6)
Clinical rheumatologic applications of reproductive immunology. Facts, fiction, and fancy. (1997) (6)
Immunologic dynamics in cryapheresis for rheumatoid arthritis. (1983) (6)
Body image mediates the impact of pain on depressive symptoms in patients with systemic lupus erythematosus (2019) (6)
Genetics of systemic lupus erythematosus. (1997) (6)
Use of autologous pregnancy plasma to treat a flare of juvenile rheumatoid arthritis: Case report and literature review (1987) (6)
The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literature (2007) (6)
Quality-of-life, legal-financial, and disability issues in fibromyalgia (2001) (6)
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (6)
The Lupus Book (1995) (6)
Celecoxib for lupus. (2008) (6)
Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al. (2010) (6)
‘Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus’ by Papadaki et al (2018) (5)
Baricitinib for systemic lupus erythematosus – Authors' reply (2019) (5)
Laboratory Features of Cutaneous Lupus Erythematosus (2005) (5)
Additional components to measuring fatigue in patients with systemic lupus erythematosus: comment on the article by the Ad Hoc Committee on systemic lupus erythematosus response criteria for fatigue. (2008) (5)
Don't dumb down lupus patient literature! (1998) (5)
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort (2021) (5)
Advances in the management of systemic lupus erythematosus. (1999) (5)
What's new in the management of lupus since 2000? (2006) (5)
Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells (2022) (5)
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE) (2021) (5)
Fibromyalgia: unusual historical aspects and new pathogenic insights. (1984) (5)
Development and validation of a preference weight multiattribute health outcome measure for rheumatoid arthritis. (2006) (5)
Cell-bound complement activation products associate with lupus severity in SLE (2020) (4)
A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus (2021) (4)
Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton et al. (1995) (4)
Immune complex mediated rheumatic diseases. (1980) (4)
Evaluating the Construct of Damage in Systemic Lupus Erythematosus (2021) (4)
How Prosorba apheresis came to be used for rheumatoid arthritis: a personal historical perspective. (2001) (4)
Editorial: Epratuzumab: Reveille or Requiem? Teachable Moments for Lupus and Sjögren's Syndrome Clinical Trials (2018) (4)
Chapter 51 – Specialized Treatment Approaches and Niche Therapies for Lupus Subsets (2013) (4)
Liver transplantation in patients with systemic lupus erythematosus (1995) (4)
New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective. (2008) (3)
Pyridostigmine for fibromyalgia: comment on the article by Paiva and a historical vignette. (2003) (3)
Neutrophils Contribute to ER Stress in Lung Epithelial Cells in the Pristane-Induced Diffuse Alveolar Hemorrhage Mouse Model (2021) (3)
The biology of aging and the immune system. (1982) (3)
PES9 ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATION (2004) (3)
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset (2021) (3)
PSY36 DEVELOPMENT OF THE LUPUS IMPACT TRACKER: A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (2011) (3)
Plasmapheresis in rheumatic diseases. (1986) (3)
Abstract 4744: CD22-targeting epratuzumab mediates trogocytosis of multiple cell-surface markers on normal, malignant, and lupus B cells. (2013) (3)
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial (2022) (3)
THU0301 Safety following initiation of rituximab in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA): interim analysis of the rituximab in anca-associated vasculitis registry (RAVER) (2017) (3)
Novel therapies in the treatment of systemic lupus erythematosus. (2001) (3)
Successful use of nitrogen mustard for cyclophosphamide resistant diffuse proliferative lupus glomerulonephritis: report of 2 cases. (1995) (3)
Survival Patterns in Systemic Lupus Erythematosus-Reply (1981) (3)
Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells (2022) (3)
New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability? (2006) (3)
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications (2021) (3)
Lupus erythematosus cell test. (1995) (3)
Biologics use in sle in 23 centers – data from the international registry for biologics in SLE (2011) (3)
Persistent eosinophilia in 2 patients with eosinophilia-myalgia syndrome. (1993) (3)
Prevalence of Fibromyalgia in Growth Hormone Deficient Adults (2001) (3)
OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL (2020) (2)
Eradication of small intestinal bacterial overgrowth decreases the gastrointestinal symptoms in fibromyalgia (2000) (2)
Safety and ef ﬁ cacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study (2015) (2)
PLASMAPHERESIS IN RAYNAUD'S DISEASE (1978) (2)
Addressing behavioral abnormalities in fibromyalgia (2006) (2)
Klinefelter's Syndrome (47,XXY) Among Men with Sjogren's Syndrome (2015) (2)
Low-dose interleukin-2 for systemic lupus erythematosus? (2019) (2)
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis (2022) (2)
Innovative Trials and New Opportunities in SLE. (2021) (2)
ADPRT ALLELES FROM THE CHROMOSOME 1q41-q42 LINKED REGION ARE ASSOCIATED WITH SLE (1998) (2)
S950 Symptomology Following SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease Relative to Healthcare Workers (2021) (2)
199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study (2019) (2)
Psychometric validation of the Arthritis Helplessness Index in systemic lupus erythematosus (2018) (2)
Cluster analysis of longitudinal treatment patterns in patients newly diagnosed with systemic lupus erythematosus in the United States (2014) (2)
Chest pain in lupus patients: the emergency department experience (2015) (2)
Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial (2019) (2)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) (2023) (2)
Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals (2022) (2)
Systemic and Biologic Agents for Lupus Erythematosus (2018) (2)
Chapter 47 – Principles of Therapy, Local Measures, and Nonsteroidal Medications (2013) (2)
Systemic lupus erythematosus. (2002) (2)
Regulation of cGAS-STING Pathway - Implications for Systemic Lupus Erythematosus (2021) (2)
What constitutes a fibromyalgia expert? (1999) (2)
Epratuzumab in SLE (2012) (2)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus (2017) (2)
S904 Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease After SARS-CoV-2 mRNA Vaccination (2021) (2)
S741 Psychological Distress During a Global Pandemic: Prevalence and Risk Factors in a National Cohort of Inflammatory Bowel Disease (IBD) Patients (2021) (2)
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus (2022) (2)
OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study (2018) (2)
New Insights Into Systemic Lupus Erythematosus Therapies: 2010-2020. (2020) (2)
A Prevalence Survey of Lupus in Moorpark, California Is There Any Evidence for a Lupus Cluster? (1998) (1)
Systemic lupus erythematosus and Sj??gren??s syndrome (1996) (1)
Clinical response to belimumab in academic clinical practices (2014) (1)
epratuzumab Trogocytosis of multiple B-cell surface markers by CD22 targeting with (2014) (1)
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic (2022) (1)
The lung in systemic lupus erythematosus (2021) (1)
Systemic lupus erythematosus, rheumatology and medical literature: current trends. (1985) (1)
Historical Vignette: Raynaud's Phenomenon as Perceived by Musculoskeletal Specialists (1862-1957) (2003) (1)
Progress toward Better Treatment of Lupus. (2022) (1)
THU0271 PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES (2020) (1)
Anti-Dense Fine Speckled 70 Autoantibodies in Systemic Lupus 1 The Prevalence and Determinants of Anti-DFS 70 Autoantibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients Running Head : Anti-Dense Fine Speckled 70 Autoantibodies in SLE 1 (2018) (1)
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis (2015) (1)
Principles of Therapy, Local Measures, and NSAIDs (2019) (1)
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study (2017) (1)
Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29]. (2017) (1)
Aging research: yesterday and today. Commentary and opinion by a medical student. (1974) (1)
Positive LE preps and negative ANA in brothers with SLE: is there still a role for the LE cell prep? A literature review. (1992) (1)
THU0286 Immunologic Response to Long-Term Epratuzumab Treatment in Sl0008, An Open-Label Long-Term Extension Study in Patients with Moderate-to-Severe Systemic Lupus Erythematosus (2013) (1)
Predictors of Seizures in Systemic Lupus Erythematosus. (2011) (1)
Prescribing trends for targeted therapies in rheumatoid arthritis among rheumatologists in Southern California, 2008-2010. (2011) (1)
Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus (2013) (1)
S742 A National Cohort of IBD Patients Exhibit Strong COVID-19 Safety Practice Beliefs (2021) (1)
Classifying Cutaneous Lupus Erythematosus (1994) (1)
To fibromyalgia nihilists: stop pontificating and test your hypothesis. (2004) (1)
What constitutes a mortality study? Comment on the article by Uramoto et al. (1999) (1)
Book Review The Fibromyalgia Syndrome: Current research and future directions in epidemiology, pathogenesis, and treatment Edited by Stanley R. Pillemer. 184 pp. Binghamton, N.Y., Haworth Press, 1995. $29.95. 1-56024-714-2 (1995) (1)
Systemic lupus erythematosus and Sjögren's syndrome: Editorial overview (1994) (1)
Cancer Risk Factors in SLE: Multivariate Regression Analysis in 16,409 Patients (2014) (1)
RETHINKING SOMATIZATION. AUTHORS' REPLY (1997) (1)
Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. (2019) (1)
Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus? (2008) (1)
The New Sjogren's Syndrome Handbook (1998) (1)
PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER (2011) (1)
COVID-19 in patients with rheumatic disease: finally, a denominator (2021) (1)
What is fibromyalgia? (2013) (1)
eNAMPT/TLR4 inflammatory cascade activation is a key contributor to SLE Lung vasculitis and alveolar hemorrhage (2022) (1)
SPECT brain imaging in patients (pts) with systemic lupus erythematosis (SLE) detects frontal lobe watershed defects: Chronic ischemia may be the basis for a cognitive decline (2006) (1)
The end of an era: a commentary on the demise of the bulletin on rheumatic diseases (1950-2004). (2004) (1)
Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus? (2006) (1)
Controversial Syndromes and Their Relationship to Fibromyalgia (2002) (1)
Immunofluorescence and fibromyalgia. (1985) (1)
EFFICACY AND SAFETY OF TABALUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM 2 PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIALS (2015) (1)
THU0283 Two Year Follow-Up on Biologics Use in 13 Centers - Data from the International Registry for Biologics in SLE (IRBIS) (2013) (1)
Does hydroxychloroquine improve patient reported outcomes in patients with lupus? (2021) (1)
Understanding Hughes Syndrome. Case Studies for Patients (2011) (1)
POS0697 SAFETY OF BELIMUMAB IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE INTEGRATED SAFETY ANALYSIS OF CONTROLLED CLINICAL TRIAL DATA (2021) (1)
Is hydroxychloroquine destined for a larger role in managing systemic lupus erythematosus? (1997) (1)
Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp‐2 cells (2013) (1)
Best Practices and Challenges to the Practice of Rheumatologists. (2019) (0)
Are patient ratings of interactions with providers and health plans associated with technical quality of care in systemic lupus erythematosus ? (2014) (0)
POS0686 BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (2021) (0)
Future management of systemic lupus erythematosus (2007) (0)
OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT (2021) (0)
CLASSIFYING CUTANEOUS LUPUS ERYTHEMATOSUS. AUTHOR'S REPLY (1994) (0)
Railway spine, posttraumatic fibromyalgia, and junk science in the courtroom (ca. 1975). (2004) (0)
Running Head : Economic Evaluation of Lupus Damage in an International Inception Cohort Title : Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach (2019) (0)
Celecoxib for lupus. Author's reply (2008) (0)
A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA (2022) (0)
Clinical Trials in Rheumatology. (2019) (0)
Comment on the article by Studenski et al. (1988) (0)
Editorial [ Why is Current Rheumatology Reviews Different that Other Rheumatology Journals? ] (2007) (0)
The management of chronic noninfectious synovitis ca. 1818. (2003) (0)
Comprar Fibromyalgia | Daniel Clauw | 9780195384413 | Oxford University Press (2010) (0)
Fighting fibromyalgia: Five key issues (2008) (0)
O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease (2020) (0)
S926 Effects of Immune Modifying Therapies on Antibody Responses Following SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease (2021) (0)
Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2017) (0)
Clinical correlates of avascular necrosis in systemic lupus erythematosus. (2001) (0)
CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells (2012) (0)
The Journal of Rheumatology Lupus Erythematosus: Results from the SLICC Inception Cohort Osteopontin and Disease Activity in Patients with Recent-onset Systemic (2019) (0)
Blood relatives with incomplete lupus are distinguished from unaffected relatives and relatives with classified disease by altered autoantibodies, soluble inflammatory and regulatory mediators, and clinical features (2016) (0)
102 M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort (2022) (0)
The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study (2015) (0)
Apheresis for Rheumatic and Other Autoimmune Conditions: Where Do We Stand? (2003) (0)
PSY205 - BODY IMAGE IN SLE AND THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND PSYCHOSOCIAL CONCERNS (2018) (0)
Microvascular Angina: An Underappreciated Cause of SLE (2013) (0)
The biology of aging: 1976, an overview (1977) (0)
Plasmapheresis for systemic lupus erythematosus. (1991) (0)
Systemic lupus erythematosus. (2002) (0)
Reply: To PMID 22556106. (2013) (0)
When thought leaders mislead: "discoid lupus is not related to SLE". (2003) (0)
Editorial [Hot Topic: At Long Last: A Viable Biomedical Model for Fibromyalgia (Daniel J. Wallace (Editor-in-Chief) ] (2007) (0)
The Sjögren's Book (2022) (0)
Cell bound complement activation products alone and in combination with low serum complement C3 or C4 have superior diagnostic performance in systemic lupus erythematosus (2019) (0)
Discovering infant logic (1986) (0)
Ten important topics relating to systemic lupus erythematosus and Sj??gren??s syndrome (1998) (0)
Patient Guide to Lupus Erythematosus (2013) (0)
Clinical applications (1995) (0)
Systemic lupus erythematosus and Sjögren's syndrome. (1997) (0)
Engaging pediatric patients and caregivers in an oral chemotherapy safety assessment. (2016) (0)
Myocardial tissue characteriation with native myocardial T1 mapping in SLE patients with chest pain (2016) (0)
The Dowling club. (1971) (0)
Autologous pregnancy plasma transfusion in RA (1993) (0)
CS-07 Economic evaluation of damage accrual in an international SLE inception cohort (2018) (0)
S7A:5 Sri response, attainment of low disease activity and safety in patients with systemic lupus treated with atacicept in a phase iib study (address ii) (2018) (0)
134 – Management of nonrenal and non–central nervous system lupus (2015) (0)
Reply (2013) (0)
O4 Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus (2020) (0)
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine (2022) (0)
Managing arthritis in the elderly. (1990) (0)
List of Contributors (2019) (0)
Soluble mediators and clinical features predict transition to systemic lupus erythematosus classification in previously unaffected relatives of SLE patients (HUM3P.243) (2015) (0)
Quality Guidelines for Systemic Lupus Erythematosus: Slow But Steady Progress (2013) (0)
Lupus for the non-rheumatologist. (1999) (0)
NeutraSal ® is clinically proven to help restore the oral environment 2 FOR PATIENTS WITH SJÖGREN ’ S SYNDROME 90 % OF PATIENTS REPORTED IMPROVEMENT IN SWALLOWING (2017) (0)
1124 Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach (2021) (0)
CE-22 Cancer in systemic lupus erythematosus: results from the slicc inception cohort (2016) (0)
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus (2015) (0)
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes (2023) (0)
The current status of therapeutic apheresis in the management of rheumatoid arthritis. (1982) (0)
A Prospective Study of Seizures in Systemic Lupus Erythematosus. (2011) (0)
Leukocytapheresis and rheumatoid arthritis: comment on the article by Hidaka et al. (1999) (0)
Suggested additions to future directions: comment on the ACR white paper on antimalarials and cardiac toxicity by Desmarais et al (2022) (0)
CE-10 Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (0)
Anti-beta2 Glycoprotein I IgA in Systemic Lupus Erythematosus Versus Controls (2011) (0)
Controversy over sclerotherapy for malignant pleural effusions. (1994) (0)
The Future Holds a Lot of Hope (2002) (0)
Diagnosis and management of central nervous system Sjögren's syndrome (2020) (0)
Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data (2022) (0)
Body Image Lupus Scale (2017) (0)
W1661 The Effect of an Increasing Body Mass Index on Health Related Quality of Life Following Esophago-Gastric Cancer Surgery (2010) (0)
在盘状红斑狼疮局部R333阶段II随机试验中,用于评估临床应答的电脑平面几何法 (2018) (0)
Gastric abnormalities in systemic lupus erythematosus (0)
Association Of ACommon Haplotype Of Complement Receptor 2(CR2) With Increased Risk Of SLE (2007) (0)
Silicone breast implants do not cause rheumatic diseases, but can they influence them? (2002) (0)
Whiplash: a case of regretting being responsible for naming a condition. (2005) (0)
Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus (2018) (0)
Can lupus low disease activity state predict mortality in patients with SLE? (2022) (0)
Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus. Clinical and Immunologic Associations (2011) (0)
Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) (2014) (0)
Altered soluble mediator levels and systemic lupus erythematosus-specific Connective Tissue Disease Screening Questionnaire (CSQ) scores differentiate unaffected relatives of lupus patients from healthy individuals with no family history of SLE (CCR4P.214) (2015) (0)
Abstract 10923: Myocardial Perfusion Reserve Measured by Adenosine Stress Magnetic Resonance Imaging in Systemic Lupus Erythematosus Patients with Angina but No Coronary Artery Disease (2010) (0)
Reply (2010) (0)
Current status of therapeutic apheresis in rheumatoid arthritis. (1981) (0)
Complementary and Alternative Medications, Specialized and Niche Therapies (2019) (0)
801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk (2021) (0)
Comprar Dubois' Lupus Erythematosus and Related Syndromes, 8th Edition | Daniel Wallace | 9781437718935 | Saunders (2012) (0)
OP-BRHE190339 860..868 (2020) (0)
ACR White Paper on Antimalarials and Cardiac Toxicity: Suggested Additions to Future Directions. (2022) (0)
212 Phase 2, randomized, double-blind, placebo-controlled, dose-finding study, evaluating the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with systemic lupus erythematosus: study design (2019) (0)
Does my daughter have lupus? (2016) (0)
Disease activity markers for SLE: is a little activity more helpful than none? (2019) (0)
Sex chromosome Aneuploides among Men with Systemic Lupus Erythematosus (2012) (0)
Insights into Insides: Chest, Cardiovascular, and Other Concerns (2002) (0)
Active idiopathic systemic lupus erythematosus in a 90-year-old woman requiring corticosteroid therapy. (1991) (0)
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort (2017) (0)
Chloroquine and cytokines. (1997) (0)
Chapter 9 – Management of Nonrenal Systemic Lupus Erythematosus 2 (2010) (0)
Rethinking Somatization (1997) (0)
Principles and Practice of Geriatric Sleep Medicine: Sleep and fibromyalgia in the elderly (2009) (0)
Belimumab: Where Are We Three Years After FDA Approval? (2015) (0)
What’s Wrong with My Muscles? (2002) (0)
Top Stories 7 Clinician ’ s Corner – Nail Capillaroscopy in SS 9 New Partnerships for 2010 SSF Student Fellowships 15 Patient Education – Anti-Inflammatory Diet (2010) (0)
1501 Genetics of age at systemic lupus erythematosus diagnosis (2021) (0)
Quantitative computerized joint scanning in rheumatoid arthritis: an accurate reproducible method of quantitating synovitis--preliminary report. (1989) (0)
Reply (2012) (0)
Chapter 32 – Management of Sjögren Syndrome in Patients with SLE (2013) (0)
1107 Economic evaluation of hydroxychloroquine use in an international inception cohort (2021) (0)
Birmingham Construction of a frailty index as a novel health measure in systemic lupus erythematosus (2019) (0)
AB0496 Corticosteroid Use across 52 Weeks of Belimumab Therapy in SLE Patients with High Disease Activity: Combined Analyses from the BLISS Trials (2014) (0)
THE UTILITY OF ADENOSINE STRESS-REST CARDIAC MAGNETIC RESONANCE IMAGING IN EVALUATING CARDIAC FUNCTION AND PERFUSION IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2010) (0)
237 Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus (2019) (0)
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study. (2014) (0)
Comment on: Additional components to measuring fatigue in patients with systemic lupus erythematosus. Author's reply (2008) (0)
Response to Letter from Dr. Maitra (2001) (0)
Anti-C1q Antibody in Systemic Lupus Erythematosus (2011) (0)
Outcome measures in systemic lupus erythematosus: constructing a meaningful response index from existing clinical trial data (2014) (0)
Editorial [Hot Topic:Neuro-Behcets Syndrome: Finally, New Insights Daniel J. Wallace ] (2007) (0)
Decreased Live Births in Women with SLE (2010) (0)
Fever therapy for arthritis. (2004) (0)
603 Remission and low disease activity are associated with lower health care costs in an international inception cohort of patients with systemic lupus erythematosus (2022) (0)
[Antimalarial agents in rheumatic diseases. New therapeutic aspects of an old medication]. (1996) (0)
Clinical impact of biologic therapy in the treatment of SLE (2013) (0)
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor (2017) (0)
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling. (2023) (0)
Cl in ic ian ’ s Corner Systemic Activity at Diagnosis of Sjögren ’ s : A Key Prognostic Marker (2015) (0)
Editorial [ UCTD and Unfinished Business ] (2006) (0)
QUANTITATIVE JOINT SCANNING IN RHEUMATOID ARTHRITIS (1981) (0)
The Professionals ’ Resource on Sjögren ’ s Syndrome First Genetic Associations Established for Sjögren ’ s (2014) (0)
Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus (2018) (0)
What constitutes a mortality study? Comment on the article by Uramoto et al [3] (multiple letters) (1999) (0)
Performance of the EULAR/ACR 2019 Classifi cation Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease (2019) (0)
SSF Clinical Practice Guidelines for Caries Prevention are Here ! (2016) (0)
Treatment of SLE : Bridging the Gap from Clinical Trials to Practice (2013) (0)
CE-21 The prevalence and determinants of ANTI-DFS70 antibodies in an international inception cohort of systemic lupus erythematosus (SLE) patients (2016) (0)
Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients (2014) (0)
version of SELENA comparison of BILAG 2004 and the flare with systemic lupus erythematosus : a An assessment of disease flare in patients (0)
POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS (2022) (0)
CONTROVERSY OVER FOR MALIGNANT PLEURAL EFFUSIONS (1994) (0)
A Paper Patient-Based Flare Study in SLE (2015) (0)
OP0252 NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY (2019) (0)
A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach (2015) (0)
Comment on the article by Lahita et al, on their finding of low plasma androgen levels in systemic lupus erythematosus (SLE) patients. (1988) (0)

This paper list is powered by the following services:

Other Resources About Daniel J. Wallace

en.wikipedia.org

What Schools Are Affiliated With Daniel J. Wallace?

Daniel J. Wallace is affiliated with the following schools: